Compare Stocks: HRTX, SLGL, SBTX, and NERV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.34 +0.7%	$0.43	$0.30 ▼ $1.58	$63.92M	1.65	2.63 million shs	1.76 million shs
NERV Minerva Neurosciences	$4.58 +16.8%	$4.46	$1.87 ▼ $12.46	$218.69M	-0.1	145,970 shs	340,008 shs
SBTX Silverback Therapeutics	$5.65 -7.4%	$7.64	$2.80 ▼ $8.97	$203.73M	0.6	337,931 shs	5.05 million shs
SLGL Sol-Gel Technologies	$84.69 +0.8%	$78.10	$15.03 ▼ $97.97	$237.97M	1.12	56,835 shs	79,397 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	0.00%	-31.40%	-29.26%	-60.39%	-75.95%
NERV Minerva Neurosciences	0.00%	+7.26%	+8.79%	-12.09%	+153.04%
SBTX Silverback Therapeutics	-7.38%	-8.28%	-25.17%	-23.91%	-66.09%
SLGL Sol-Gel Technologies	0.00%	-3.76%	+8.47%	+16.46%	+448.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$0.34 +0.7%	$0.43	$0.30 ▼ $1.58	$63.92M	1.65	2.63 million shs	1.76 million shs
NERV Minerva Neurosciences	$4.58 +16.8%	$4.46	$1.87 ▼ $12.46	$218.69M	-0.1	145,970 shs	340,008 shs
SBTX Silverback Therapeutics	$5.65 -7.4%	$7.64	$2.80 ▼ $8.97	$203.73M	0.6	337,931 shs	5.05 million shs
SLGL Sol-Gel Technologies	$84.69 +0.8%	$78.10	$15.03 ▼ $97.97	$237.97M	1.12	56,835 shs	79,397 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	0.00%	-31.40%	-29.26%	-60.39%	-75.95%
NERV Minerva Neurosciences	0.00%	+7.26%	+8.79%	-12.09%	+153.04%
SBTX Silverback Therapeutics	-7.38%	-8.28%	-25.17%	-23.91%	-66.09%
SLGL Sol-Gel Technologies	0.00%	-3.76%	+8.47%	+16.46%	+448.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	2.00	Hold	$2.00	494.00% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	125.62% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
SLGL Sol-Gel Technologies	2.67	Moderate Buy	$197.50	133.20% Upside

Current Analyst Ratings Breakdown

Latest HRTX, SLGL, SBTX, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/20/2026	SLGL Sol-Gel Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	SLGL Sol-Gel Technologies	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$285.00
6/4/2026	SLGL Sol-Gel Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
6/3/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.00
6/2/2026	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$151.18M	0.42	N/A	N/A	$0.03 per share	11.22
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
SLGL Sol-Gel Technologies	$19.39M	12.27	N/A	N/A	$8.19 per share	10.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A
SLGL Sol-Gel Technologies	-$6.13M	-$0.34	N/A	N/A	N/A	-5.66%	-3.17%	-2.58%	8/21/2026 (Estimated)

Latest HRTX, SLGL, SBTX, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2026	Q2 2026	SLGL Sol-Gel Technologies	-$2.36	N/A	N/A	N/A	$0.08 million	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
5/28/2026	Q1 2026	SLGL Sol-Gel Technologies	-$2.86	-$1.31	+$1.55	$1.31	$0.90 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	24.35	2.49	1.51
NERV Minerva Neurosciences	N/A	20.15	17.65
SBTX Silverback Therapeutics	N/A	67.87	67.87
SLGL Sol-Gel Technologies	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
NERV Minerva Neurosciences	34.56%
SBTX Silverback Therapeutics	74.89%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	6.10%
NERV Minerva Neurosciences	1.70%
SBTX Silverback Therapeutics	34.40%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.81 million	941,000	No Data

HRTX, SLGL, SBTX, and NERV Headlines

Recent News About These Companies

Sol-Gel Technologies (SLGL) to Announce Earnings on Friday

August 14 at 1:10 AM | americanbankingnews.com

Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday

August 14 at 1:10 AM | marketbeat.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages

August 12, 2026 | marketbeat.com

Affinity Asset Advisors LLC Purchases Shares of 35,000 Sol-Gel Technologies Ltd. $SLGL

July 25, 2026 | marketbeat.com

Sol-Gel Technologies Insider Trading Activity | NASDAQ:SLGL | Benzinga

July 23, 2026 | benzinga.com

HC Wainwright Issues Positive Estimate for SLGL Earnings

July 22, 2026 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Sol-Gel Technologies (NASDAQ:SLGL)

July 20, 2026 | marketbeat.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 229 Shares

July 11, 2026 | insidertrades.com

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in Stock

July 3, 2026 | insidertrades.com

Sol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho Securities

June 26, 2026 | theglobeandmail.com

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

May 30, 2026 | theglobeandmail.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

May 28, 2026 | zacks.com

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 28, 2026 | globenewswire.com

Insider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of Stock

May 15, 2026 | insidertrades.com

Sol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary Shares

March 23, 2026 | quiverquant.comQ

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

March 23, 2026 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates

March 19, 2026 | zacks.com

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

March 19, 2026 | globenewswire.com

This Under-the-Radar Stock Has Surged 1,300% Over the Past Year

March 13, 2026 | finance.yahoo.com

Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year

February 11, 2026 | finance.yahoo.com

Sol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20

February 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SLGL, SBTX, and NERV Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$0.34 +0.00 (+0.69%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.35 +0.01 (+3.06%)

As of 08/14/2026 07:34 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Minerva Neurosciences NASDAQ:NERV

$4.58 +0.66 (+16.84%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.64 +0.06 (+1.31%)

As of 08/14/2026 07:34 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Silverback Therapeutics NASDAQ:SBTX

$5.65 -0.45 (-7.38%)

As of 08/14/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Sol-Gel Technologies NASDAQ:SLGL

$84.69 +0.65 (+0.77%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$84.15 -0.54 (-0.64%)

As of 08/14/2026 07:34 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, SLGL, SBTX, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, SLGL, SBTX, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, SLGL, SBTX, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SLGL, SBTX, and NERV Company Descriptions

Heron Therapeutics NASDAQ:HRTX

Minerva Neurosciences NASDAQ:NERV

Silverback Therapeutics NASDAQ:SBTX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, SLGL, SBTX, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, SLGL, SBTX, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, SLGL, SBTX, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, SLGL, SBTX, and NERV Company Descriptions

Heron Therapeutics NASDAQ:HRTX

Minerva Neurosciences NASDAQ:NERV

Silverback Therapeutics NASDAQ:SBTX

Sol-Gel Technologies NASDAQ:SLGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools